Mohamed Hesham Gamal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed Hesham Gamal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abdelrahaman G. Tawfik
Department of Pharmacotherapy College of Pharmacy, University of Utah Salt Lake City Utah USA
1 shared publication Abdelrahman A. Abdelhameed
South Warwickshire NHS Foundation Trust, Warwick, UK
1 shared publicationAbdelrahman Mohamed
Guys and St Thomas’ NHS Foundation Trust, London, UK
1 shared publicationAhmed A. Farag
King Abdullah Medical City, Mecca, Saudi Arabia
1 shared publication- Ahmed Hashem Fathallah
Faculty of Medicine, Minia University, Minia, Egypt
1 shared publication - Ahmed Marey
Shaikh Khalifa Medical City, Abu Dhabi, Abu Dhabi, United Arab Emirates
1 shared publication
Latest Publications
- 10 November 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- p. 1-24
Safety and clinical outcomes of intravenous thrombolysis in stroke mimics compared with acute ischemic stroke: A systematic review and meta-analysis
Intravenous thrombolysis (IVT) is the cornerstone of hyperacute care for acute ischemic stroke (AIS); however, increasingly compressed door-to-needle times mean some stroke mimics (SM) receive thrombolysis. We compared safety, mortality, functional, and disposition outcomes of IVT in SM versus confirmed AIS and assessed whether baseline neurological deficit severity modified these outcomes. We searched five databases up to June 2026 for IVT outcomes in adult SM versus AIS. We assessed risk of bias using the Newcastle–Ottawa Scale and the Cochrane Risk of Bias 2 (RoB-2) tool. We pooled 95% confidence intervals (CIs) using fixed- or random-effects models in R, with subgroup analyses by baseline National Institutes of Health Stroke Scale (NIHSS) score (≤ 7 versus > 7). Twenty-seven cohort studies and one RCT were included, involving approximately 285,000 patients. Compared with AIS, SM had significantly lower odds of symptomatic intracranial hemorrhage (OR 0.18; 95% CI 0.12–0.27), any intracranial hemorrhage (OR 0.12; 0.07–0.22), in-hospital mortality (OR 0.24; 0.06–0.94), and 3-month mortality (OR 0.24; 0.15–0.39). SM were also more likely to achieve functional independence (mRS 0–1) at discharge (OR 12.04) and 3 months (OR 3.50) and to be discharged home (OR 3.46), with shorter hospital stays (MD − 1.96 days). The hemorrhage reduction was greatest among milder deficits (NIHSS ≤ 7). IVT in stroke mimics carries substantially lower hemorrhagic and mortality risk and better functional outcomes than in AIS, reflecting the benign nature of mimics rather than a treatment effect. Diagnostic uncertainty should not delay or withhold IVT in otherwise eligible patients. Graphical Abstract
- 10 November 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- p. 1-24
Safety and clinical outcomes of intravenous thrombolysis in stroke mimics compared with acute ischemic stroke: A systematic review and meta-analysis
Intravenous thrombolysis (IVT) is the cornerstone of hyperacute care for acute ischemic stroke (AIS); however, increasingly compressed door-to-needle times mean some stroke mimics (SM) receive thrombolysis. We compared safety, mortality, functional, and disposition outcomes of IVT in SM versus confirmed AIS and assessed whether baseline neurological deficit severity modified these outcomes. We searched five databases up to June 2026 for IVT outcomes in adult SM versus AIS. We assessed risk of bias using the Newcastle–Ottawa Scale and the Cochrane Risk of Bias 2 (RoB-2) tool. We pooled 95% confidence intervals (CIs) using fixed- or random-effects models in R, with subgroup analyses by baseline National Institutes of Health Stroke Scale (NIHSS) score (≤ 7 versus > 7). Twenty-seven cohort studies and one RCT were included, involving approximately 285,000 patients. Compared with AIS, SM had significantly lower odds of symptomatic intracranial hemorrhage (OR 0.18; 95% CI 0.12–0.27), any intracranial hemorrhage (OR 0.12; 0.07–0.22), in-hospital mortality (OR 0.24; 0.06–0.94), and 3-month mortality (OR 0.24; 0.15–0.39). SM were also more likely to achieve functional independence (mRS 0–1) at discharge (OR 12.04) and 3 months (OR 3.50) and to be discharged home (OR 3.46), with shorter hospital stays (MD − 1.96 days). The hemorrhage reduction was greatest among milder deficits (NIHSS ≤ 7). IVT in stroke mimics carries substantially lower hemorrhagic and mortality risk and better functional outcomes than in AIS, reflecting the benign nature of mimics rather than a treatment effect. Diagnostic uncertainty should not delay or withhold IVT in otherwise eligible patients. Graphical Abstract
- Open Access
- 10 October 2025
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Case Reports
- Vol. 2 (2) , 20-25
Multimodal Conservative Management of Nulliparous Female with Cervical Ectopic Pregnancy: A Case Report
Cervical ectopic pregnancy is an extremely rare condition with catastrophic sequelae if timely, appropriate management is not performed. Some risk factors predispose patients to this condition, but in our case, no predisposing risk factors were present. Nulliparity and young age are the most challenging points for fertility conservation, and multimodal conservative management is a highly successful option for appropriately selected patients. A 22-year-old nulliparous patient presented to our tertiary university hospital for a viable 8-week cervical ectopic pregnancy after failure of treatment with two doses of methotrexate. Confirmation of the diagnosis was achieved, and our team selected a multimodal conservative management approach. During admission, severe bleeding was recognized early on, and the patient was successfully handled with satisfactory fertility preservation outcomes. Fertility preservation is the most challenging point when dealing with cervical ectopic pregnancy, especially in young nulliparous women. However, the best way to manage cervical ectopic pregnancy has not yet been confirmed, and multimodal conservative management can be an effective method.
- 10 October 2025
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Case Reports
- Vol. 2 (2) , 20-25
Open AccessMultimodal Conservative Management of Nulliparous Female with Cervical Ectopic Pregnancy: A Case Report
Cervical ectopic pregnancy is an extremely rare condition with catastrophic sequelae if timely, appropriate management is not performed. Some risk factors predispose patients to this condition, but in our case, no predisposing risk factors were present. Nulliparity and young age are the most challenging points for fertility conservation, and multimodal conservative management is a highly successful option for appropriately selected patients. A 22-year-old nulliparous patient presented to our tertiary university hospital for a viable 8-week cervical ectopic pregnancy after failure of treatment with two doses of methotrexate. Confirmation of the diagnosis was achieved, and our team selected a multimodal conservative management approach. During admission, severe bleeding was recognized early on, and the patient was successfully handled with satisfactory fertility preservation outcomes. Fertility preservation is the most challenging point when dealing with cervical ectopic pregnancy, especially in young nulliparous women. However, the best way to manage cervical ectopic pregnancy has not yet been confirmed, and multimodal conservative management can be an effective method.
- Open Access
- 25 August 2025
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 59 (2) , 104-107
Prothrombin Complex Concentrate versus Frozen Plasma in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis
Ahmed Nazmy, M.D., Mohamed Hesham Gamal, M.D., Hesham Elharti, M.D., Ahmed Sobhy, M.D., Ahmed Yasser Shaban, M.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.056
- 25 August 2025
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 59 (2) , 104-107
Open AccessProthrombin Complex Concentrate versus Frozen Plasma in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis
Ahmed Nazmy, M.D., Mohamed Hesham Gamal, M.D., Hesham Elharti, M.D., Ahmed Sobhy, M.D., Ahmed Yasser Shaban, M.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.056
- Open Access
- 1 August 2023
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 59 (1) , 154-166
Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.
- 1 August 2023
- Published by Canadian Society of Respiratory Therapists in Canadian Journal of Respiratory Therapy
- Vol. 59 (1) , 154-166
Open AccessInhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.